Compare Baxter International Inc (BAX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Royal Caribbean Cruises Ltd — how do they compare? Baxter International Inc trades at $22.34 (market cap $11.26B), while Royal Caribbean Cruises Ltd trades at $294.9 (market cap $75.92B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 6.7× Baxter International Inc's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| BAX | RCL | |
|---|---|---|
Market Cap | $11.26B | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.22 | $365.84 |
52-Week Low | $15.80 | $246.71 |
Enterprise Value | $18.93B | $97.20B |
Dividend Yield | 0.92% | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Royal Caribbean (RCL) trades at $288.61, up 1.14% today, with a bullish technical setup near key resistance at $292. The company demonstrates strong fundamental momentum, with 2025 revenue reaching $17.93 billion and net income surging to $4.27 billion, yielding a robust 24.36% net margin. Analyst consensus is positive, with a $328 price target implying 14% upside, supported by 25 buy ratings. Recent news highlights Caribbean demand strength offsetting European softness, with Q2 2026 earnings due July 28.
RCL's outlook is favorable, driven by earnings beats, expanding margins, and strategic destination investments. Key risks include Europe demand volatility, high debt levels, and competitive pressures. Institutional sentiment leans bullish, but macroeconomic sensitivity and execution on yield growth remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
